investor relations
corporate profile
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.
4
FDA-APPROVED INDICATIONS
35,000+
PATIENTS TREATED THROUGH JANUARY 2025
$605M
ANNUAL NET REVENUES (2024)
$210M
ANNUAL R&D INVESTMENTS (2024)
5
ONGOING PHASE 2 AND PHASE 3 TRIALS
press releases
latest quarterly reports
latest filings
reports
See our online annual reports and more.
corporate governance
mission, vision and values
mission
vision
contact us
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.